Skip to main content

Pollen Allergy

1
Pipeline Programs
2
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Allergopharma
AllergopharmaGermany - Reinbek
1 program
1
birch pollen allergoidPhase 3
Mabylon
MabylonSwitzerland - Schlieren
1 program
blood withdrawalN/A1 trial
Active Trials
NCT03727399Enrolling By Invitation300Est. Dec 2025

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Mabylonblood withdrawal

Clinical Trials (1)

Total enrollment: 300 patients across 1 trials

NCT03727399Mabylonblood withdrawal

Identification of Allergen-reactive Antibodies in the Blood of Pollen Allergic Patients

Start: Oct 2018Est. completion: Dec 2025300 patients
N/AEnrolling By Invitation

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.